1017234-25-1

Basic information

• Product Name: 3-[(1S)-1-{methyl[(1S)-1-phenylethyl]amino}ethyl]phenyl N-ethyl-N-methylcarbamate
• Synonyms: 3-[(1S)-1-{methyl[(1S)-1-phenylethyl]amino}ethyl]phenyl N-ethyl-N-methylcarbamate
• CAS NO: 1017234-25-1
• Molecular Weight: 340.466
• Mol File: 1017234-25-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-[(1S)-1-{methyl[(1S)-1-phenylethyl]amino}ethyl]phenyl N-ethyl-N-methylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[(1S)-1-{methyl[(1S)-1-phenylethyl]amino}ethyl]phenyl N-ethyl-N-methylcarbamate(1017234-25-1)
• EPA Substance Registry System: 3-[(1S)-1-{methyl[(1S)-1-phenylethyl]amino}ethyl]phenyl N-ethyl-N-methylcarbamate(1017234-25-1)

Safety Data

• Hazardous Substances Data: 1017234-25-1(Hazardous Substances Data)

Upstream product

• 42252-34-6 N-ethyl-N-methylcarbamoyl chloride 
• 1017234-23-9 (1S)-N-((S)-1-(3-hydroxyphenyl)ethyl)-N-methyl-1-phenylethanamine 
• 2627-86-3 (S)-1-phenyl-ethylamine 
• 855300-09-3 1-(N-ethyl-N-methylaminocarbonyloxy)-3-acetylbenzene 
• 50-00-0 formaldehyd 

Downstream Products

• 923035-05-6 (S)-3-[1-(methylamino)ethyl]-phenyl N-ethyl-N-methyl-carbamate 

Relevant articles and documents

Novel convenient synthesis of rivastigmine

A novel and convenient synthesis of rivastigmine has been reported. This procedure provides high yield and excellent enantiomeric excess (100% ee) starting from the diastereromerically pure (S)-1-(3-methoxyphenyl)-N-[(S)-1- phenylethyl] ethanamine. Copyright Taylor & Francis Group, LLC.

PREPARATION METHOD OF RIVASTIGMINE, ITS INTERMEDIATES AND PREPARATION METHOD OF THE INTERMEDIATES

The present invention provides N-methylethylcarbamino-3-[(S)-1-(methyl-[(S)-1-phenylethyl] amino) ethyl] phenyl ester represented by formula (II) and its preparation method. The present invention also provides (S)-1-(3-methoxyphenyl)-N-methyl-N-[(S)-1-phenylethyl] ethylamine and 3-[(S)-1-(methyl-[(S)-1-phenylethyl] amino) ethyl] phenol as intermediates of the compound represented by formula (II), and the use of the compound represented by formula (II) for preparing rivastigmine used for treating Alzheimer disease.